Beaded plasma clot: A potent sustained-release, drug-delivery system

Therapeutic Delivery

Volumn 2, Issue 5, 2011, Pages 573-583

  Ahmad, Ejaj ^a   Fatima, Munazza T ^a   Owais, Mohammad ^a   Saleemuddin, Mohammad ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CALCIUM CHLORIDE; CEFOTAXIME; DAUNORUBICIN; FUNGICIN; GLUTARALDEHYDE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOT; CONTROLLED STUDY; CROSS LINKING; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RABBIT; SUSTAINED DRUG RELEASE;

EID: 79956155440     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.30     Document Type: Article

References (55)

1. Lorand L. Cross links in blood: Transglutaminase and beyond. FASEB J. 21, 1627-1632 (2007). (Pubitemid 46855608)
2. Doillon CJ. Methods of tissue engineering. In:Modification of Natural Polymers: Fibrinogen-fibrin. Atala A, Lanza RP (Eds). Academic Press, CA, USA, 555-563 (2002).
3. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest. 57, 673-686 (1987). (Pubitemid 18031786)
4. Radosevich M, Goubran HI, Burnouf T. Fibrin sealant: Scientific rationale, production methods, properties, and current clinical use. Vox Sang. 72, 133-143 (1997). (Pubitemid 27187368)
5. Wong C, Inman E, Spaethe R, Helgerson S. Fibrin based biomaterials to deliver human growth factors. Thromb. Haemost. 89, 573-582 (2003). (Pubitemid 36329250)
6. Spotnitz WD, Burks SG, Prabhu R. Fibrin-based adhesives and hemostatic agents. In:Tissue Adhesives in Clinical Medicine. Quinn JV (Ed.). BC Decker, Hamilton, Ontario, Canada, 77-112 (2005).
7. Martin NE, Kim JW, Abramson DH. Fibrin sealant for retinoblastoma: Where are we? J. Ocul. Pharmacol. Ther. 24, 433-438 (2008).
8. Janmey PA, Winer JP, Weisel JW. Fibrin gels and their clinical and bioengineering applications. J. R. Soc. Interface 6, 1-10 (2009).
9. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 96, 3772-3778 (2000).
10. Campbell PG, Durham SK, Hayes JD, Suwanichkul A, Powell DR. Insulin-like growth factor-binding protein-3 binds to fibrinogen and fibrin. J. Biol. Chem. 274, 30215-30221 (1999).
11. Thompson DF, Davis TW. The addition of antibiotics to fibrin glue. Southern Med. J. 90, 681-684 (1997). (Pubitemid 27304703)
12. Senderoff RI, Sheu MT, Sokoloski TD. Fibrin based drug delivery systems. J. Parenter. Sci. Technol. 45, 2-6 (1991).
13. Dillon JG, Wage CW, Daly WH. Enzyme immobilization on fibrin. Biotechnol. Bioeng. 18, 133-139 (1976).
14. Itokazu M, Yamamoto K, Yang WY, Aoki T, Kato N, Watanabe K. The sustained release of antibiotic from freeze dried fibrin antibiotic compound and efficacies in a rat model of osteomylitis. Infection 25, 359-363 (1997). (Pubitemid 27507305)
15. Deyerling W, Haverich A, Potel J, Hetzer R. A suspension of fibrin glue and antibiotic for local treatment of mycotic aneurysms in endocarditis: An experimental study. Thorac. Cardiovasc. Surg. 32, 369-372 (1984). (Pubitemid 15182459)
16. Frucht-Perry J, Assil KK, Ziegler E et al. Fibrin-enmeshed tobramycin liposomes: Single application topical therapy of Pseudomonas keratitis. Cornea 11, 393-397 (1992).
17. Woolverton CJ, Fulton JA, Salstrom SJ et al. Tetracycline delivery from fibrin controls peritoneal infection without measurable systemic antibiotic. J. Antimicrob. Chemother. 48, 861-867 (2001). (Pubitemid 33735322)
18. Trombelli L, Scabbia A, Wikesjo UM, Calura G. Fibrin glue application in conjunction with tetracycline root conditioning and coronally positioned flap procedure in the treatment of human gingival recession defects. J. Clin. Periodontol. 23, 861-867 (1996).
19. Nichols W. Adverse antibody-mediated reactions to topical bovine thrombin and fibrin glue. In: Fibrin Sealant: Characteristics and Clinical Uses. Proceedings of the Uniformed Services, University of Health Sciences. USA Department of the Army, Food and Drug Administration, and National Institutes of Health, USA, 5-10 (1994).
20. Jackson MR. Fibrin sealants in surgical practice: An overview. Am. J. Surg. 182, 1S-7S (2001). (Pubitemid 32898601)
21. Bale MD, Mosher DF. Effects of thrombospondin on fibrin polymerization and structure. J. Biol. Chem. 261, 862-868 (1986). (Pubitemid 16161752)
22. Stoscheck CM. Quantization of protein. Methods Enzymol. 182, 50-68 (1990).
23. Mehta TR, Hopfer LR, McQueen T, Juliano LR, Lopez-Berestein G. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. 31, 1901-1903 (1987). (Pubitemid 18009558)
24. Kumar TR, Vasantha Bhai M, Krishnan KL. A freeze-dried fibrin disc as a biodegradable drug release matrix. Biologicals 32, 49-55 (2004). (Pubitemid 38333184)
25. Simeonova M, Ivanova G, Enchev V et al. Physicochemical characterization and in vitro behavior of daunorubicin-loaded poly(butylcyanoacrylate) nanoparticles. Acta Biomater. 5, 2109-2121 (2009).
26. Aguero J, Peris, J-E, San-Martin E. Validation of a high-performance chromatographic method for determination of cefotaxime in biological samples. Forens. J. Anal. Chem. 363, 289-293 (1999).
27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685 (1970).
28. Ho HO, Hsiao CC, Sokoloski TD, Chen CY, Sheu MT. Fibrin based drug delivery systems III: The evaluation for the release of macromolecules from microbeads. J. Control. Rel. 34, 65-70 (1995).
29. Brajtburg JS, Elberg S, Bolard J et al. Interaction of plasma proteins and lipoproteins with amphotericin B. J. Infect. Dis. 149, 986-997 (1984). (Pubitemid 14082164)
30. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walse TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46, 834-840 (2002). (Pubitemid 34157671)
31. Karakusis PH, Trenholme GM, Levin S. A review of the use of cefotaxime in the treatment of skin structure infections, with special reference to Gram-positive pathogens. Infection 13, S46-S49 (2005).
32. Tidrick RT, Warner ED. Fibrin fixation of skin transplants. Surgery 15, 90-95 (1944).
33. Suzuki K, Iwata M, Ito S, Matsui K, Uchida A, Mizoi Y. Molecular basis for subtypic differences of the "a" subunit of coagulation factor XIII with description of the genesis of the subtypes. Hum. Genet. 94, 129-135 (1994). (Pubitemid 24232043)
34. Baumann RE, Henschen AH. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: Identification of polymorphisms at positions A α 312 and B β 448. Blood 82, 2117-2124 (1993). (Pubitemid 23293995)
35. Nakamura S, Sawaguchi A. Factor I (IF) polymorphism in the Japanese population: Existence of a new variant and quantitative analysis of different allotypes. Gene Geogr. 5, 45-50 (1991).
36. Van der Velden PA, Krommenhoek-Van Es T, Allaart CF, Bertina RM, Reitsma PH. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia. Thromb. Haemost. 65, 511-513 (1991).
37. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: Implications for efficiency and consistency of removal of B19 DNA during manufacture. Br. J. Haematol. 93, 714-719 (1996).
38. Redl H, Schlag G, Stanek G, Hirschl A, Seelich T. In vitro properties of mixture of fibrin seal and antibiotics. Biomaterials 4, 29-32 (1983). (Pubitemid 13131827)
39. Greco F, de Palma L, Spagnolo N, Rossi A, Specchia N, Gigante A. Fibrin antibiotic mixtures: An in vitro study assessing the possibility of using a biologic carrier for local drug delivery. J. Biomed. Mater. Res. 25, 39-51 (1991).
40. Marone P, Monzillo V, Segu C, Antoniazzi E. Antibiotic-impregnated fibrin glue in ocular surgery: In vitro antibacterial activity. Ophthalmologica 213, 12-15 (1999). (Pubitemid 28561778)
41. Boyce ST, Holder IA, Supp AP, Warden GD, Greenhalgh DG. Delivery and activity of antimicrobial drugs released from human fibrin sealant. J. Burn. Care Rehabil. 15, 251-255 (1994). (Pubitemid 24148305)
42. Woolverton CJ, Huebert K, Burkhart B, MacPhee M. Subverting bacterial resistance using high dose, low solubility antibiotics in fibrin. Infection 27, 28-33 (1999). (Pubitemid 29054376)
43. Gorodetsky R, Peylan-Ramu N, Reshef A, Gaberman E, Levdansky L, Marx G. Interactions of carboplatin with fibrin(ogen), implications for local slow release chemotherapy. J. Control. Release 102, 235-245 (2005). (Pubitemid 40093788)
44. Alam SMM, Rahman MM, Rahman MH, Rahman NN. Tetracycline hydrochloride binds with high affinity to warfarin site (site-I) on bovine serum albumin: Temperature and pH influence the binding process. Pakistan J. Biol. Sci. 7, 2099-2104 (2004).
45. Bodey GP. Infectious complications in cancer patient. Curr. Probl. Cancer 1, 3-63 (1977).
46. Edwards JE Jr, Lehrer RI, Stiehm ER, Fischer TJ, Young LS. Severe candidal infections: Clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann. Intern. Med. 89, 91-106 (1978). (Pubitemid 8365449)
47. Gondal JA, Swartz RP, Rahman A. Therapeutic evaluation of free and liposome encapsulated amphotericine B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 33, 1544-1548 (1989). (Pubitemid 19228011)
48. Graybill JR, Craven PC, Taylor RL, Williams DM, Mager WE. Treatment of murine cryptococcsis with liposome associated amphotericin B. J. Infect. Dis. 145, 748-752 (1982). (Pubitemid 12116465)
49. Wang SS, Yang MC, Chung TW. Liposomes/chitosan scaffold/human fibrin composite systems for delivering hydrophilic drugs-release behaviors of tirofiban. Drug Deliv. 15, 149-157 (2008).
50. Gaudreault RC, Bellemare B, Lacroix J. Erythrocyte membrane bound daunorubicin as a delivery system in anticancer treatment. Anticancer Res. 9, 1201-1205 (1989).
51. Sung HW, Chang WH, Ma CY, Lee MH. Crosslinking of biological tissues using genepin and/or carbodiamide. J. Biomed. Mater. Res. 64, 427-438 (2003).
52. Sell SA, Francis MP, Garg K, McClure MJ, Simpson DG, Bowlin GL. Cross-linking methods of electrospun fibrinogen scaffolds for tissue engineering applications. Biomed. Mater. 3, 1-11(2008).
53. Yoshida H, Yamaoka Y, Shinoyama M, Kamiya A. Novel drug delivery system using autologous fibrin glue release properties of anti-cancer drugs. Biol. Pharm. Bull. 23, 371-374 (2000). (Pubitemid 30187292)
54. Clark RA. Fibrin glue for wound repair: Facts and fancy. Thromb. Haemost. 90, 1003-1006 (2003). (Pubitemid 38004417)
55. Bergel S. Ueberwkungen des Fibrins. Dtsch. Wochenschr. 35, 633-665 (1909).